Vertex Pharmaceuticals Incorporated (VRTX) Income Statement

NASDAQ: VRTXRevenue, profits, margins and EPS over 10 years.

VRTX 2025 at a glance

Fiscal year ended December 31, 2025 · U.S. dollars
Revenue+9.6%
$12.07B
2025 · hover or tap a bar for each year
2016: $1.70B (+64.9%)2017: $2.49B (+46.2%)2018: $3.05B (+22.5%)2019: $4.16B (+36.6%)2020: $6.21B (+49.1%)2021: $7.57B (+22.1%)2022: $8.93B (+17.9%)2023: $9.87B (+10.5%)2024: $11.02B (+11.7%)2025: $12.07B (+9.6%)
20162025
Gross profit+8.2%
$10.27B
2025 · hover or tap a bar for each year
2016: $1.49B (+64.5%)2017: $2.21B (+48.4%)2018: $2.64B (+19.2%)2019: $3.62B (+37.0%)2020: $5.47B (+51.3%)2021: $6.67B (+22.0%)2022: $7.85B (+17.7%)2023: $8.61B (+9.6%)2024: $9.49B (+10.3%)2025: $10.27B (+8.2%)
20162025
Operating income
$4.76B
2025 · hover or tap a bar for each year
2016: $9.9M2017: $123.2M (+1,140.4%)2018: $635.1M (+415.4%)2019: $1.20B (+88.5%)2020: $2.86B (+138.5%)2021: $2.78B (−2.6%)2022: $4.31B (+54.8%)2023: $3.83B (−11.0%)2024: −$232.9M (−106.1%)2025: $4.76B
20162025
Net income
$3.95B
2025 · hover or tap a bar for each year
2016: −$112.1M2017: $263.5M2018: $2.10B (+695.8%)2019: $1.18B (−43.9%)2020: $2.71B (+130.4%)2021: $2.34B (−13.6%)2022: $3.32B (+41.8%)2023: $3.62B (+9.0%)2024: −$535.6M (−114.8%)2025: $3.95B
20162025
EPS (diluted)+6,248.3%
$18.41
2025 · hover or tap a bar for each year
2016: $0.842017: $2.86 (+240.5%)2018: $4.09 (+43.0%)2019: $5.33 (+30.3%)2020: $10.32 (+93.6%)2021: $13.02 (+26.2%)2022: $14.89 (+14.4%)2023: $15.22 (+2.2%)2024: $0.29 (−98.1%)2025: $18.41 (+6,248.3%)
20162025
Net profit margin+37.6 pts
32.7%
2025 · hover or tap a point for each year
2016: −6.6% (+47.5 pts)2017: 10.6% (+17.2 pts)2018: 68.8% (+58.2 pts)2019: 28.3% (−40.5 pts)2020: 43.7% (+15.4 pts)2021: 30.9% (−12.8 pts)2022: 37.2% (+6.3 pts)2023: 36.7% (−0.5 pts)2024: −4.9% (−41.5 pts)2025: 32.7% (+37.6 pts)
20162025

VRTX revenue and net income

RevenueNet incomeNet margin (right axis)

Where VRTX's revenue goes

2025
Revenue
$12.07B100.0%
Cost of revenue
−$1.81B−15.0%
Gross profit
$10.27B85.0%
Research & development
−$3.75B−31.1%
Sales, general & admin
−$1.75B−14.5%
Operating income
$4.76B39.4%
Interest & other expense
−$117.5M−1.0%
Income taxes
−$690.0M−5.7%
Net income
$3.95B32.7%

Each bar shows an amount and its share of revenue. VRTX kept 32.7% of revenue as net income.

VRTX profit margins

GrossOperatingNet

VRTX growth rates

to 2025
1 year3 years5 years10 years
Revenue+9.6%+10.6%+14.2%+27.9%
Gross profit+8.2%+9.4%+13.4%+27.5%
Operating income—+3.4%+10.8%—
Net income—+6.0%+7.8%—
EPS (diluted)+6,248.3%+7.3%+12.3%—

1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.

VRTX quarterly EPS vs estimates

Reported EPSAnalyst estimate

Vertex beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 2, 2026 (estimate $4.35).

VRTX income statement

Vertex Pharmaceuticals Incorporated annual income statement
2025202420232022202120202019201820172016
Revenue$12.07B$11.02B$9.87B$8.93B$7.57B$6.21B$4.16B$3.05B$2.49B$1.70B
Cost of revenue$1.81B$1.53B$1.26B$1.08B$904.2M$736.3M$547.8M$409.5M$275.1M$210.5M
Gross profit$10.27B$9.49B$8.61B$7.85B$6.67B$5.47B$3.62B$2.64B$2.21B$1.49B
Research & development$3.75B$3.63B$3.16B$2.66B$3.05B$1.83B$1.75B$1.42B$1.32B$1.05B
Sales, general & admin$1.75B$1.46B$1.14B$887.2M$840.1M$770.5M$658.5M$557.6M$496.1M$432.8M
Total operating expenses$5.51B$9.72B$4.78B$3.54B$3.89B$2.61B$2.41B$1.97B$1.82B$1.48B
Operating income$4.76B−$232.9M$3.83B$4.31B$2.78B$2.86B$1.20B$635.1M$123.2M$9.9M
Interest income$490.9M$598.1M$614.7M$144.6M$4.9M$22.2M$63.7M$33.5M$57.5M$81.4M
Interest expense$13.3M$30.6M$44.1M$54.8M$61.5M$58.2M$58.5M$34.1M$69.3M$81.4M
Income before taxes$4.64B$248.5M$4.38B$4.23B$2.73B$3.12B$1.39B$600.2M−$15.7M−$67.4M
Income taxes$690.0M$784.1M$760.2M$910.4M$388.3M$405.2M$218.1M−$1.49B−$107.3M$16.7M
Net income$3.95B−$535.6M$3.62B$3.32B$2.34B$2.71B$1.18B$2.10B$263.5M−$112.1M
EBITDA$4.87B$486.3M$4.61B$4.44B$2.92B$3.28B$1.56B$706.8M$103.3M$75.5M
EPS (diluted)$18.41$0.29$15.22$14.89$13.02$10.32$5.33$4.09$2.86$0.84
Gross margin85.0%86.1%87.2%87.9%88.1%88.1%86.8%86.6%88.9%87.6%
Operating margin39.4%−2.1%38.8%48.2%36.7%46.0%28.8%20.8%5.0%0.6%
Net margin32.7%−4.9%36.7%37.2%30.9%43.7%28.3%68.8%10.6%−6.6%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in VRTX's financial statements (latest annual report filed February 13, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.

VRTX financial results

In fiscal year 2025 (ended December 31, 2025), Vertex reported revenue of $12.1 billion, up 9.6% from the year before. It had net income of $4.0 billion, a net profit margin of 32.7%. Diluted earnings per share came to $18.41. Over five years revenue grew at an average rate of 14.2% a year.

See the VRTX stock overview for the latest quote and news, or the VRTX chart for price history and technical indicators.

VRTX income statement FAQ

What is Vertex's annual revenue?

Vertex reported total revenue of $12.1 billion for fiscal year 2025, which ended on December 31, 2025. That was up 9.6% from $11.0 billion the previous year.

Is Vertex profitable?

Yes. Vertex reported net income of $4.0 billion in fiscal 2025, a net profit margin of 32.7%; its operating margin was 39.4%.

What is Vertex's gross margin?

Vertex's gross margin was 85.0% in fiscal 2025: for every $100 of revenue, Vertex kept $85 after the direct cost of its products and services.

How much does Vertex spend on research and development?

Vertex spent $3.8 billion on research and development in fiscal 2025, 31.1% of revenue.

How fast is Vertex growing?

Revenue grew 14.2% a year on average over the last five fiscal years, from $6.2 billion to $12.1 billion.

What are Vertex's earnings per share?

Vertex earned $18.41 per diluted share in fiscal 2025, compared with $0.29 a year earlier.

When will Vertex report its next earnings?

Vertex is expected to report results for the quarter ending September 30, 2026 on November 2, 2026 after the market closes.

When does Vertex's fiscal year end?

Vertex's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 13, 2026.

Biotechnology income statements